NCT02145611View on ClinicalTrials.gov

Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Type 2 Diabetes MellitusHypertensionEndothelial Dysfunction
Interventions
DRUG

Glibenclamide

Glibenclamide

DRUG

Vildagliptin

Vildagliptin

Trial Locations (1)

15090-000

Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Dr. José Fernando Vilela-Martin MD PhD

OTHER

NCT02145611 - Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension | Biotech Hunter | Biotech Hunter